Kab Tak Midcaps smallcaps microcaps shant Rahega
Jaldi He Time aayega inka bhi
Stay Tunned
Budget ke Pehle can we see upmove??
Possibility are High
Jaldi He Time aayega inka bhi
Stay Tunned
Budget ke Pehle can we see upmove??
Possibility are High
Wealthcreatures.com
Vikram Thermo Days Low - 57.05 All dips are buying opportunity
VIKRAM THERMO
10% 🆙
64.50 💚
Highest closing level till Now
10% 🆙
64.50 💚
Highest closing level till Now
In 2023 a "DIP" will come 💯 definitely ...can we see Dip near by Feb - March - April
But abhi to TEZI ka maja lelo
Currently Not a Good Time for Bears
&
Individual PF also Down currently as only Index moving
But abhi to TEZI ka maja lelo
Currently Not a Good Time for Bears
&
Individual PF also Down currently as only Index moving
Wealthcreatures.com
VIKRAM THERMO 10% 🆙 64.50 💚 Highest closing level till Now
Vikram Thermo
Fresh 52wk High
66.85
Watchout for close above 6⃣6⃣ 🚀
Fresh 52wk High
66.85
Watchout for close above 6⃣6⃣ 🚀
Wealthcreatures.com
Hazoor Multi Projects Cmp - 68.35 Market cap - 66cr Q1FY23 Sales - 203 cr vs Q4FY22 Sales - 89 cr TTM Sales - 304 cr Posted Q1 Net Profit of 6 cr Received order in July 2022, worth 220 cr which is yet to be executed. As on Jan 31 2022, Hazoor Multi…
HAZOOR MULTI PROJECTS LTD
FRESH ATH
Locked 🔒 in 5% UC
101.90
FRESH ATH
Locked 🔒 in 5% UC
101.90
16,900x Growth in Just 20 Years is Just Amazing
Focus on Growth stocks
But Sustained Growth stocks
Power of compounding
Needs lots and lots of patience & Vision( To hold stock till the time when there is no growth)
₹1 Lakh Invested In August 2002, ₹169 Crores Today 💰
Stock Name: Titan Company Ltd.
🔅 Dividends, Bonus Shares and Buybacks
A stock price surge is not the only way investors can make money. Here are a few other ways:
➕ Bonus Shares: When investors get additional shares at no extra cost.
🪙 Dividends: Monetary reward given to investors for staying invested in the company.
🔙 Share Buybacks: The company decides to buy its own shares back from investors.
🪓 Stock Splits: A single share turns into multiple shares without affecting the market capitalisation of the company.
⏳ A Stock That Stood The Test Of Time
🔅In the last 20 years, a single share of Titan has yielded 845% returns. But that's not all. Here's how this brilliant stock rewarded its investors.
👉🏽 Bonus Shares + Stock Split
On 23rd June 2011, the company announced bonus shares in the ratio of 1:1 and a stock split of 10:1. A stock split does not result in direct profit for the investor—it increases the number of shares an investor has but reduces the cost of the initial investment.
👉🏽 Cost Price Decrease
The input cost of the investors who purchased Titan's shares 20 years ago, in August 2002, decreased to 10% of their real cost as Titan announced a 10:1 stock split in June 2011. Therefore, the cost price for shareholders who invested 20 years ago further decreased by 50%, given the issue of bonus shares. As a result of the stock split, their input cost was already estimated at 10% of the total cost. Their cost price was further reduced to 5% of their real purchasing level by the bonus share issue.
👉🏽 Astronomical Growth
Due to the 10:1 stock split and 1:1 bonus share announcement, investors actually paid ₹0.15 for each share, rather than the original price of ₹3. For these investors, Titan's share price multiplied by 16,900 times in the last 20 years.
Stock Value
August 2002: ₹3
August 2022: ₹2535
NOVEMBER 2022 : ₹2650
Focus on Growth stocks
But Sustained Growth stocks
Power of compounding
Needs lots and lots of patience & Vision( To hold stock till the time when there is no growth)
₹1 Lakh Invested In August 2002, ₹169 Crores Today 💰
Stock Name: Titan Company Ltd.
🔅 Dividends, Bonus Shares and Buybacks
A stock price surge is not the only way investors can make money. Here are a few other ways:
➕ Bonus Shares: When investors get additional shares at no extra cost.
🪙 Dividends: Monetary reward given to investors for staying invested in the company.
🔙 Share Buybacks: The company decides to buy its own shares back from investors.
🪓 Stock Splits: A single share turns into multiple shares without affecting the market capitalisation of the company.
⏳ A Stock That Stood The Test Of Time
🔅In the last 20 years, a single share of Titan has yielded 845% returns. But that's not all. Here's how this brilliant stock rewarded its investors.
👉🏽 Bonus Shares + Stock Split
On 23rd June 2011, the company announced bonus shares in the ratio of 1:1 and a stock split of 10:1. A stock split does not result in direct profit for the investor—it increases the number of shares an investor has but reduces the cost of the initial investment.
👉🏽 Cost Price Decrease
The input cost of the investors who purchased Titan's shares 20 years ago, in August 2002, decreased to 10% of their real cost as Titan announced a 10:1 stock split in June 2011. Therefore, the cost price for shareholders who invested 20 years ago further decreased by 50%, given the issue of bonus shares. As a result of the stock split, their input cost was already estimated at 10% of the total cost. Their cost price was further reduced to 5% of their real purchasing level by the bonus share issue.
👉🏽 Astronomical Growth
Due to the 10:1 stock split and 1:1 bonus share announcement, investors actually paid ₹0.15 for each share, rather than the original price of ₹3. For these investors, Titan's share price multiplied by 16,900 times in the last 20 years.
Stock Value
August 2002: ₹3
August 2022: ₹2535
NOVEMBER 2022 : ₹2650
Sakar Healthcare
Yest Low - 230
Today's Low - 235
Recent 15 days Low - 225
Stock trying to form a Good Base for next Upmove
More strength on close above 250
Yest Low - 230
Today's Low - 235
Recent 15 days Low - 225
Stock trying to form a Good Base for next Upmove
More strength on close above 250
🔅Sakar Healthcare is a pharmaceutical company incorporated in 2004. They do contract manufacturing majorly for sterile drugs and they also export to various emerging markets under their own brands
🔅Sakar Healthcare manufacture a variety of dosage forms including Liquid Injections, Lyophilized Injections, Dry Powder Injections, Dry Powder Syrups and Oral Solids Like Tablets and Capsules. Their biggest therapy area is Antibiotics which contributes to 41% of revenues,followed by Vitamins (15%), Antimalarial (14%), Anti infectives (5%), Antacid (4%) and Laxative (4%). In antibiotics, the majority of their revenues come from the Cephalosporins.
🔶Business Segments:
Sakar has 3 business segments viz. Contract Manufacturing(CMO), Exports and Loan Licensing. Under CMO, they manufacture drugs for big pharmaceutical companies including Zydus, Intas, Baxter, Torrent, Merck, Ferring Pharma, Ipca Labs, Indoco Remedies, etc.
Under the export segment, the sell drugs under their own brands to 53 countries in APAC, Latin America, East & French- West Africa, CIS, Europe, etc. They sell their products through over 75 distribution partners.
Under the Loan Licensing segment, they collect fees from customers for doing conversion and packaging of finished formulations.
🔶Foray into Oncology:
The company has entered the oncology segment by setting up a greenfield facility in Bavla, Gujarat - about 15 minutes away from the existing facility. It is an integrated facility with in-house R&D, API and formulation manufacturing.
They have installed modern technologies in this facility like flow chemistry and are trying to develop green chemistries. They will be manufacturing Oral Solids (Tablets and Capsules) and Injections (Liquid and Lyophilized).
The R&D, API and oral solids units have been commercialized and the injectables unit is expected to come online by March 2023. The OSD and API units have received WHO GMP approval.
They will be exporting the drugs under their own brands as well as contract manufacturing for their partners. The company has already signed an agreement with Zydus for the manufacture of oncology drugs
🔶Capex:
The company undertook a capex of ₹194 Cr for setting up the greenfield facility for oncology. To fund this capex, the company has availed debt of ₹95 Cr. They also raised funds through equity sale to Swiss PE fund - HBM Healthcare.
HBM initially invested ₹14.85 Cr in March 2021 and then invested ₹24 Cr in June 2022. The balance amount will be funded through internal accruals and promoter’s contribution. Management has said that they expect 3X asset turns from this capex.
🔶Guidance:
The management has said that they are expecting additional ₹600 Cr coming from oncology alone in 4-5 years with 30% EBITDA margins. They are aiming for a ₹500 Cr topline by 2026 with 60-65% revenues coming from oncology.
🔶Risks Involved :
The company will be facing a lot of competition from much larger companies in the oncology segment. Players like Natco Pharma have already commercialized all the molecules the company is planning to launch and operate in the same markets the company plans to sell its products. The promoters also have another company - Bisil Plast which is into PET bottle manufacturing and is not traded anymore.
🔅Sakar Healthcare manufacture a variety of dosage forms including Liquid Injections, Lyophilized Injections, Dry Powder Injections, Dry Powder Syrups and Oral Solids Like Tablets and Capsules. Their biggest therapy area is Antibiotics which contributes to 41% of revenues,followed by Vitamins (15%), Antimalarial (14%), Anti infectives (5%), Antacid (4%) and Laxative (4%). In antibiotics, the majority of their revenues come from the Cephalosporins.
🔶Business Segments:
Sakar has 3 business segments viz. Contract Manufacturing(CMO), Exports and Loan Licensing. Under CMO, they manufacture drugs for big pharmaceutical companies including Zydus, Intas, Baxter, Torrent, Merck, Ferring Pharma, Ipca Labs, Indoco Remedies, etc.
Under the export segment, the sell drugs under their own brands to 53 countries in APAC, Latin America, East & French- West Africa, CIS, Europe, etc. They sell their products through over 75 distribution partners.
Under the Loan Licensing segment, they collect fees from customers for doing conversion and packaging of finished formulations.
🔶Foray into Oncology:
The company has entered the oncology segment by setting up a greenfield facility in Bavla, Gujarat - about 15 minutes away from the existing facility. It is an integrated facility with in-house R&D, API and formulation manufacturing.
They have installed modern technologies in this facility like flow chemistry and are trying to develop green chemistries. They will be manufacturing Oral Solids (Tablets and Capsules) and Injections (Liquid and Lyophilized).
The R&D, API and oral solids units have been commercialized and the injectables unit is expected to come online by March 2023. The OSD and API units have received WHO GMP approval.
They will be exporting the drugs under their own brands as well as contract manufacturing for their partners. The company has already signed an agreement with Zydus for the manufacture of oncology drugs
🔶Capex:
The company undertook a capex of ₹194 Cr for setting up the greenfield facility for oncology. To fund this capex, the company has availed debt of ₹95 Cr. They also raised funds through equity sale to Swiss PE fund - HBM Healthcare.
HBM initially invested ₹14.85 Cr in March 2021 and then invested ₹24 Cr in June 2022. The balance amount will be funded through internal accruals and promoter’s contribution. Management has said that they expect 3X asset turns from this capex.
🔶Guidance:
The management has said that they are expecting additional ₹600 Cr coming from oncology alone in 4-5 years with 30% EBITDA margins. They are aiming for a ₹500 Cr topline by 2026 with 60-65% revenues coming from oncology.
🔶Risks Involved :
The company will be facing a lot of competition from much larger companies in the oncology segment. Players like Natco Pharma have already commercialized all the molecules the company is planning to launch and operate in the same markets the company plans to sell its products. The promoters also have another company - Bisil Plast which is into PET bottle manufacturing and is not traded anymore.
Wealthcreatures.com
TIMKEN FRESH ATH 2830 💚 Next 3189 & 3475+
TIMKEN INDIA 🇮🇳
20% 🆙 🔒 IN UC
3500 ➕️
Next Test Levels- 3776/4141/4500+
20% 🆙 🔒 IN UC
3500 ➕️
Next Test Levels- 3776/4141/4500+
Wealthcreatures.com
Best Agro Super Numbers
BEST AGRO
Launch of just 1 new product propelled sales by >100%, they have a pipeline of 27 new products to be introduced in coming years
Trading Cheap Vs Growth Outlook
Promoter bought from the open market yesterday
Stock is in uptrend
Launch of just 1 new product propelled sales by >100%, they have a pipeline of 27 new products to be introduced in coming years
Trading Cheap Vs Growth Outlook
Promoter bought from the open market yesterday
Stock is in uptrend
Wealthcreatures.com
Late update Best Agro Lows - 1329 Fresh ATH - 1457 Closed @ 1430 Recent Lows - 1271 on 14th Oct ( Our 1st Support zone ReTest @ 1290) Was 🆙 8% yesterday Coming out of almost 1 year of consolidation Now Ready for Fresh Upmove
BEST AGRO
Won't be suprised to see at 2500 - 3000+ in next 1 year
Won't be suprised to see at 2500 - 3000+ in next 1 year
Wealthcreatures.com
Lots of Query on Deepak fertliser It's Test Levels etc We expect Good Q2 numbers and possible 1500/1800 by next Diwali And In next 2 to 3 years won't be suprise to see it 3000+ Real Growth would start in 2024
DEEPAK FERTLISER
Cmp at Days Low - 760
Available at 30% Discount from ATH Of 1064
200 DMA around 710 - 715 zone
Shld Retest sub 700 zone and this can be buying opportunity
Add in SIP on Dips
Good Risk Reward Ratio
Can expect ATH again in next 2 to 4 Qtrs
One Good Qtr and stock can See Good RUN UP
Cmp at Days Low - 760
Available at 30% Discount from ATH Of 1064
200 DMA around 710 - 715 zone
Shld Retest sub 700 zone and this can be buying opportunity
Add in SIP on Dips
Good Risk Reward Ratio
Can expect ATH again in next 2 to 4 Qtrs
One Good Qtr and stock can See Good RUN UP